Agios Pharmaceuticals, Inc. (AGIO) stock analysis
In our weekly check, Agios Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 9.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as AGIO.
What our checks show for AGIO
Red flags
- The net margin fell by 265 points over 5 years, to -265%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money: the net margin is -265%.
- Free cash flow is negative (-239% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 121% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 87% from a peak. Would you have held through that?
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- A small company (market value $1.89 billion): usually riskier and followed by fewer analysts.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0.03x equity.
- The gross margin is 91.9% and has risen by 91.9 points: pricing power is holding.
- Analysts expect revenue to grow about 75.3% a year over the next years.
- Analysts expect the net margin to improve by 254 points from today's -265%.
- Revenue grew 115% a year over the last 3 years.
- Beta 0.63: the stock usually moves less than the market.
Next earnings report: 2027-02-11
Similar companies
ZBIO · MAZE · FTRE · TRVI · ZYME
Questions
What grade does Agios Pharmaceuticals, Inc. (AGIO) have?
In our weekly check, Agios Pharmaceuticals, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 3, red flags: 9. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of AGIO stock?
This week's biggest flags for Agios Pharmaceuticals, Inc.: Margins falling, Weak EPS forecast, Weak EPS growth. In total 12 of 21 checks show a warning or a red flag.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as AGIO.
When does Agios Pharmaceuticals, Inc. report earnings next?
The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis